Director/PDMR Shareholding

RNS Number : 0033N

Creo Medical Group PLC

27 May 2022

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

Director/PDMR Shareholding

Chief Financial Officer purchases 70,000 shares; Non-Executive Chairman purchases 15,435 shares

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it has received notification that Charles Spicer, Non-Executive Chairman of Creo, and Richard Rees, Chief Financial Officer, have purchased ordinary shares of £0.001 each in the Company ("Ordinary Shares").

Charles Spicer has purchased a total of 15,435 ordinary shares at a price of 97.18p per ordinary share. Following this transaction, Charles Spicer's total direct interest in the Company held via his Self-Invested Personal Pension ("SIPP") is now 143,411 ordinary shares, representing approximately 0.08% of the Company's issued share capital. 

Richard Rees has purchased a total of 70,000 ordinary shares at a price of 96.75p per ordinary share; 21,400 of these shares are held via his SIPP. Richard Rees' total direct interest in the Company is now 73,615 ordinary shares, representing 0.04% of the Company's issued share capital.

Enquiries:

Creo Medical Group plc	www.creomedical.com
Richard Rees (CFO)	[phone]
Cenkos Securities plc	[phone]
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Numis Securities Limited (Joint Broker) Freddie Barnfield / James Black / Duncan Monteith	[phone]
Walbrook PR Ltd	Tel: + 44 ( 0)20 7933 8780 or [e-mail]
Paul McManus / Sam Allen  / Phillip Marriage	Mob: [phone]

About Creo Medical 

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions.  CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Charles Spicer
2	Reason for the notification
a)	Position/status	Non-Executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Creo Medical Group plc
b)	LEI	213800H188ZDCWWXFA21
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.001 each
	Identification code	GB00BZ1BLL44
b)	Nature of the transaction	Purchase of Ordinary Shares via SIPP
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			97.18p	15,435
d)	Aggregated information
	- Aggregated volume	N/A - single transaction
	- Price
e)	Date of the transaction	26 May 2022
f)	Place of the transaction	London Stock Exchange

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Richard Rees
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Creo Medical Group plc
b)	LEI	213800H188ZDCWWXFA21
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.001 each
	Identification code	GB00BZ1BLL44
b)	Nature of the transaction	Purchase of Ordinary Shares Purchase of Ordinary Shares via SIPP
c)	Price(s) and volume(s)	Price(s) Volume(s) 96.75p 48,600 96.75p 21,400
d)	Aggregated information
	- Aggregated volume	70,000
	- Price	£67,725.00
e)	Date of the transaction	26 May 2022
f)	Place of the transaction	London Stock Exchange

 

END

 

 

DSHFLFEAESIRFIF